• Nabil F Darwich, Jessica M Phan, Boram Kim, EunRan Suh, John D Papatriantafyllou, Lakshmi Changolkar, Aivi T Nguyen, Caroline M O'Rourke, Zhuohao He, Sílvia Porta, Garrett S Gibbons, Kelvin C Luk, Sokratis G Papageorgiou, Murray Grossman, Lauren Massimo, David J Irwin, Corey T McMillan, Ilya M Nasrallah, Camilo Toro, Geoffrey K Aguirre, Vivianna M Van Deerlin, and Edward B Lee.
• Translational Neuropathology Research Laboratory, Department of Pathology and Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania, PA, USA.
• Science. 2020 Nov 20; 370 (6519).

AbstractNeurodegeneration in Alzheimer's disease (AD) is closely associated with the accumulation of pathologic tau aggregates in the form of neurofibrillary tangles. We found that a p.Asp395Gly mutation in VCP (valosin-containing protein) was associated with dementia characterized neuropathologically by neuronal vacuoles and neurofibrillary tangles. Moreover, VCP appeared to exhibit tau disaggregase activity in vitro, which was impaired by the p.Asp395Gly mutation. Additionally, intracerebral microinjection of pathologic tau led to increased tau aggregates in mice in which p.Asp395Gly VCP mice was knocked in, as compared with injected wild-type mice. These findings suggest that p.Asp395Gly VCP is an autosomal-dominant genetic mutation associated with neurofibrillary degeneration in part owing to reduced tau disaggregation, raising the possibility that VCP may represent a therapeutic target for the treatment of AD.Copyright © 2020 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.

29 keywords...

hide…